Adenocarcinoma of the colon is the most common type of cancer affecting the large intestine, and managing it requires a thoughtful combination of surgery, medication, and sometimes newer approaches being tested in clinical trials.

How Treatment Decisions Are Made

When someone is diagnosed with adenocarcinoma of the colon, the main goal of treatment is to remove the cancer, slow down its growth, and help the person live as comfortably and fully as possible. The specific approach depends on several factors, including how far the cancer has spread, where exactly it is located in the colon, and the person’s overall health and preferences. Stage is a term doctors use to describe how much cancer is present in the body and whether it has moved beyond its original location.^[1]

For many people, especially those whose cancer is found early, surgery offers the best chance of cure. In other cases, treatment includes a combination of surgery, chemotherapy, and newer therapies designed to target specific features of cancer cells. Medical societies, like those in the United States and Europe, have developed guidelines that doctors follow to choose the safest and most effective treatment for each person.^[10]

While standard treatments have been used successfully for many years, researchers are constantly working to develop new drugs and methods that might work even better. These experimental treatments are evaluated in clinical trials, which are carefully controlled research studies that test whether new therapies are safe and effective. Some patients may have the opportunity to take part in these trials, gaining access to cutting-edge treatments before they become widely available.^[9]

Standard Treatment Approaches

Surgery as the Main Treatment

For colon adenocarcinoma, surgery is the cornerstone of treatment. The type of surgery depends on where the tumor is located in the colon. If the cancer is in the right side of the colon, doctors perform what is called a right hemicolectomy, which removes the affected part of the colon along with nearby lymph nodes and blood vessels. For tumors in the left side or in the lower part of the colon, different surgical approaches are used, such as a left hemicolectomy or sigmoid colectomy. The goal is always to remove the entire tumor with enough surrounding healthy tissue to ensure all cancer cells are gone.^[1][15]

Surgery can be curative for patients with localized disease, meaning cancer that has not spread to other organs. Even in some cases where cancer has spread to the liver or lungs, surgery to remove those tumors may still offer a chance of cure or significantly extend life. However, the decision to operate in advanced cases is complex and depends on many factors, including the number and location of tumors, and the person’s overall health.^[15]

Chemotherapy for Different Stages

Chemotherapy means using medications that kill cancer cells or stop them from growing. These drugs travel through the bloodstream, reaching cancer cells throughout the body. In colon adenocarcinoma, chemotherapy is used in different situations depending on the stage of disease.^[9]

For patients with stage III disease—where cancer has spread to nearby lymph nodes—chemotherapy given after surgery is now standard treatment. This is called adjuvant chemotherapy because it is added to surgery to reduce the risk of cancer coming back. The most commonly used drug combination includes 5-fluorouracil (often called 5-FU), which is a type of medication that interferes with cancer cells’ ability to make new DNA. This drug is often combined with leucovorin, which makes 5-FU work better, and sometimes with another drug called oxaliplatin. These combinations have been shown to improve survival rates significantly.^[10]

In stage II disease—where the tumor has grown through the colon wall but has not spread to lymph nodes—the decision about chemotherapy is more complicated. Not everyone with stage II disease needs chemotherapy, but it may be recommended for people who have certain risk factors that make the cancer more likely to return. These risk factors might include a tumor that has caused a blockage, a tumor that has grown into nearby organs, or certain features seen under the microscope.^[10]

For stage IV disease, where cancer has spread to distant organs like the liver or lungs, chemotherapy is the main treatment. It cannot usually cure the cancer, but it can shrink tumors, relieve symptoms, and help people live longer. Several chemotherapy drugs may be used, often in combination. Treatment continues as long as it is helping and the person is tolerating it reasonably well.^[9]

Targeted Therapies and Immunotherapy

Beyond traditional chemotherapy, newer types of medications have been developed that work in more specific ways. Targeted therapies are drugs designed to attack specific features of cancer cells. For colon cancer, several targeted drugs are now approved and used regularly.^[14]

Bevacizumab is a drug that blocks the growth of new blood vessels that tumors need to survive and grow. It works by targeting a protein called VEGF. This drug is often combined with chemotherapy for advanced colon cancer and can help shrink tumors and slow disease progression.^[14]

Two other drugs, cetuximab and panitumumab, target a protein on the surface of cancer cells called EGFR. These drugs are used in patients whose tumors have certain genetic characteristics. Before using these medications, doctors test the tumor to see if it has mutations in genes called KRAS, NRAS, and BRAF. If certain mutations are present, these drugs won’t work, so testing is essential.^[14]

Immunotherapy is a type of treatment that helps the immune system recognize and attack cancer cells. For colon cancer, immunotherapy works particularly well in patients whose tumors have a feature called high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These features occur in about 5 to 15 percent of colon cancers and indicate that the tumor has many genetic errors, making it easier for the immune system to recognize as abnormal.^[14]

Several immunotherapy drugs called checkpoint inhibitors are now approved for colon cancer with MSI-H or dMMR. These include pembrolizumab, nivolumab, and dostarlimab. These drugs block proteins called PD-1 or PD-L1 that cancer cells use to hide from the immune system. In some patients, these drugs can cause tumors to shrink dramatically and may work for a long time with fewer side effects than chemotherapy. Nivolumab can also be combined with another immunotherapy drug called ipilimumab, which blocks a different checkpoint protein called CTLA-4.^[14]

Side Effects and Duration of Treatment

All cancer treatments can cause side effects, though not everyone experiences them the same way. Chemotherapy side effects depend on which drugs are used but may include fatigue, nausea, diarrhea, mouth sores, hair loss, and increased risk of infection because the drugs affect healthy cells as well as cancer cells. Oxaliplatin can cause numbness and tingling in the hands and feet, which may improve after treatment ends but sometimes persists.^[11]

Targeted therapies have their own side effects. Bevacizumab can increase blood pressure and, rarely, cause bleeding or blood clots. Cetuximab and panitumumab often cause an acne-like skin rash, which can actually be a sign that the drug is working.^[14]

Immunotherapy side effects are different from chemotherapy. Because these drugs activate the immune system, they can sometimes cause the immune system to attack healthy parts of the body, leading to inflammation in the lungs, intestines, liver, or hormone-producing glands. Most of these side effects can be managed with medications, including steroids if needed.^[14]

The duration of adjuvant chemotherapy after surgery is typically three to six months, depending on the stage and the drugs used. For advanced disease, treatment may continue as long as it is helping and side effects are manageable, which could be many months or even years.^[10]

Promising Treatments in Clinical Trials

Researchers around the world are working to develop new treatments for colon adenocarcinoma. Many innovative therapies are currently being tested in clinical trials at major cancer centers in the United States, Europe, and other regions. These studies help determine whether new drugs are safe, how well they work, and how they compare to standard treatments.^[11]

Understanding Clinical Trial Phases

Clinical trials happen in phases. Phase I trials test a new treatment in a small group of people for the first time, mainly to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more people and focus on whether the treatment works against the cancer while continuing to monitor safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to see if the new approach is better, the same, or possibly worse.^[11]

New Targeted Therapies

One exciting area of research involves drugs that target specific genetic mutations found in some colon cancers. For example, some tumors have mutations in a gene called KRAS, which is one of the most common mutations in colon cancer but has been difficult to target with drugs. Recently, new medications called KRAS inhibitors have been developed. These drugs are designed to block the abnormal protein produced by mutated KRAS genes and are being tested in clinical trials for patients whose tumors have specific KRAS mutations.^[15]

Another target is the BRAF gene. About 8 to 10 percent of colon cancers have a BRAF mutation, and these cancers tend to be more aggressive. Drugs that inhibit BRAF protein are being studied, often in combination with other targeted drugs that block related pathways in cancer cells. Early results from some trials have shown promise, with tumors shrinking in some patients.^[14]

Scientists are also developing drugs called TRK inhibitors that target cancers with rare genetic changes called NTRK gene fusions. These changes can occur in colon cancer, though they are uncommon. When present, TRK inhibitors can be very effective, causing tumors to shrink in many patients.^[15]

Expanding Immunotherapy Use

While immunotherapy already works well for colon cancers with MSI-H or dMMR, most colon cancers do not have these features, and immunotherapy alone does not work well for them. Researchers are testing ways to make immunotherapy effective for these other tumors. Some studies are combining immunotherapy drugs with chemotherapy, targeted therapies, or other immunotherapy drugs to see if combinations work better than single agents.^[14]

One approach being studied is combining checkpoint inhibitors with drugs that target VEGF or other growth pathways. The idea is that blocking blood vessel growth or certain cancer cell signals might make tumors more visible to the immune system. Early phase trials are testing these combinations in patients whose tumors do not have MSI-H.^[11]

Another strategy involves vaccines designed to train the immune system to recognize and attack colon cancer cells. These are not prevention vaccines like those for infectious diseases, but treatment vaccines given to people who already have cancer. Several vaccine approaches are in early clinical trials.^[14]

Other Innovative Approaches

Some clinical trials are testing entirely new types of treatment. For example, gene therapy involves introducing genetic material into cancer cells or immune cells to change how they behave. Some gene therapy approaches aim to correct genetic defects in cancer cells, while others modify a patient’s immune cells to better recognize and attack cancer.^[11]

Researchers are also studying drugs that work by interfering with specific molecules inside cancer cells that control cell division and survival. These include inhibitors of proteins involved in DNA repair, cell metabolism, or cell death pathways. By blocking these proteins, the drugs can slow cancer growth or make cancer cells more sensitive to other treatments.^[11]

Another area of investigation is finding better ways to use existing drugs. Some trials are testing whether giving immunotherapy before surgery (called neoadjuvant therapy) can shrink tumors and prevent cancer from coming back better than giving it after surgery. Others are studying whether shorter or longer durations of chemotherapy might be just as effective with fewer side effects.^[11]

Participating in Clinical Trials

Patients interested in clinical trials should discuss this option with their doctor. Eligibility for trials depends on many factors, including the type and stage of cancer, previous treatments, and overall health. Trials are conducted at cancer centers throughout the United States, Europe, and many other countries. Some trials are specifically looking for patients with certain genetic features in their tumors, so genetic testing may be required.^[9]

Participating in a clinical trial means contributing to medical knowledge that may help future patients. However, it’s important to understand that experimental treatments may not work better than standard treatments, and they may have unexpected side effects. All clinical trials have strict rules to protect participants and ensure their safety.^[9]

Most common treatment methods

• Surgery
  • Right hemicolectomy for tumors in the cecum and right colon, removing affected tissue along with lymphatic drainage areas
  • Extended right hemicolectomy for lesions in the proximal or middle transverse colon
  • Left hemicolectomy for tumors in the splenic flexure and left colon
  • Sigmoid colectomy for sigmoid colon lesions, dividing the inferior mesenteric artery
  • Potentially curative for localized disease (stage I-III) and selected cases of metastatic disease in liver or lung
• Chemotherapy
  • 5-fluorouracil (5-FU) combined with leucovorin as a standard regimen
  • Oxaliplatin added to 5-FU/leucovorin for improved outcomes
  • Adjuvant chemotherapy standard for stage III disease, reducing recurrence risk
  • Used selectively in stage II disease for patients with high-risk features
  • Primary treatment for stage IV disease to shrink tumors and extend survival
  • Treatment duration typically three to six months after surgery, or ongoing for advanced disease
• Targeted Therapy
  • Bevacizumab blocks VEGF/VEGFR pathway, inhibiting tumor blood vessel growth for advanced disease
  • Cetuximab and panitumumab target EGFR pathway in patients with specific genetic profiles
  • Ramucirumab targets VEGF/VEGFR2 pathway for advanced cases
  • BRAF kinase inhibitors for tumors with BRAF mutations
  • TRK inhibitors for cancers with NTRK gene fusions
  • KRAS inhibitors being tested in clinical trials for specific KRAS mutations
• Immunotherapy
  • Pembrolizumab, nivolumab, and dostarlimab block PD-1/PD-L1 pathway for MSI-H or dMMR tumors
  • Ipilimumab blocks CTLA-4 pathway, often combined with nivolumab
  • Particularly effective for tumors with high microsatellite instability or mismatch repair deficiency
  • Can be used as first-line treatment in eligible patients
  • Combinations of different immunotherapy drugs being tested in clinical trials
• Radiation Therapy
  • Limited role in colon adenocarcinoma treatment
  • Used primarily for palliative care to treat metastases in bone or brain